Jennifer Kim, MD
Pediatric Allergy/Immunology · Glenview, ILNPI 1790748473
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Kaleo, Inc. accounts for 89.0% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $12,833, more than ten times the $805 reported in 2019.
Across 29 payments — averaging $559.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kaleo, Inc.$14K
- GSK$824
- Johnson & Johnson$376
- Aimmune Therapeutics, Inc.$175
- AstraZeneca$112
- Blueprint Medicines Corporation$107
- plus $185 from 5 others
What the payments were for
- Consulting fees$6,10038%
- Speaking & faculty fees$6,27539%
- Travel & lodging$2,72817%
- Food & beverage$1,0967%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kaleo, Inc. | 13 | $14,442 |
| GSK | 2 | $824 |
| Johnson & Johnson | 3 | $376 |
| Aimmune Therapeutics, Inc. | 1 | $175 |
| AstraZeneca | 1 | $112 |
| Blueprint Medicines Corporation | 1 | $107 |
| Mylan Pharmaceuticals Inc. | 2 | $63 |
| Bayer | 2 | $41 |
| Agile Therapeutics, Inc. | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Channel Medsystems, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few pediatric allergy/immunology providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 24 | $87,932 |
| TezspireTezepelumab-Ekko | 12 | $54,277 |
| XolairOmalizumab | 25 | $50,972 |
| NucalaMepolizumab | 12 | $43,883 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $30,832 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $15,573 |
| Arnuity ElliptaFluticasone Furoate | 18 | $6,492 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $5,621 |
| Azelastine Hcl | 30 | $1,851 |
| Fluticasone Propionate | 46 | $1,099 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $1,093 |
| Montelukast Sodium | 55 | $1,023 |
| Omeprazole | 17 | $191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $824 | $96,78068 claims |
| AstraZenecaTezspire, Symbicort | $112 | $59,89824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric allergy/immunology providers in Illinoison file to place this against a meaningful peer group, so we don't.
Other pediatric allergy/immunology in Glenview
- James MoyChicago$4K
- Steve HandoyoChicago$4K
- Abigail LangChicago$4K
- Michael SherenianChicago$1K
- Tori LyChicago$1K
- Rajesh KumarChicago$1K
- Fatima KhanChicago$834
- James SenterChicago$387
- Dipika PatelChicago$317
- Megan EliosChicago$235
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.